PL EN


Preferences help
enabled [disable] Abstract
Number of results
2007 | 54 | 2 | 307-313
Article title

pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice

Content
Title variants
Languages of publication
EN
Abstracts
EN
The extracellular domain of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) may function as a soluble cytokine to selectively kill various cancer cells without toxicity to most normal cells. We used a high-biosafety plasmid pVAX1 as a vector and constructed a recombinant plasmid expressing the extracellular domain (95-281 aa) of human TRAIL fused with signal peptides of human IgG╬│, designated as pVAX-sT. Transduction of human BEL7402 liver cancer cells with pVAX-sT led to high levels of sTRAIL protein in the cell culture media and induced apoptosis. The therapeutic potential of pVAX-sT was then evaluated in the BEL7402 transplanted naked mouse model. Subsequent intratumoral administration of naked pVAX-sT resulted in the expression of soluble TRAIL in the sera and the tumor site, as well as effective suppression of tumor growth, with no toxicity to liver. In conclusion, the successful inhibition of liver cancer growth and the absence of detectable toxicity suggest that pVAX-sT could be useful in the gene therapy of liver cancer.
Year
Volume
54
Issue
2
Pages
307-313
Physical description
Dates
published
2007
received
2007-01-10
revised
2007-05-08
accepted
2007-05-22
(unknown)
2007-06-04
References
  • Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162.
  • Bramson JL, Hitt M, Gauldie J, Graham FL (1997) Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther 4: 1069-1076.
  • Huang X, Lin T, Gu J, Zhang L, Roth JA, Liu J, Fang B (2003) Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene. Int J Oncol 22: 1241-1245.
  • Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960.
  • Imboden M, Shi F, Pugh TD (2003) Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther 14: 1037-1048.
  • Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor related apoptosis-inducing ligand. Nat Med 6: 564-567.
  • Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B (2001) Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 61: 3330-3338.
  • Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA (2001) Preclinical studies to predict the disposition of TRAIL in humans: Characterization of in vivo efficacy, pharmacokinetics and safety. J Pharmacol Exp Ther 299: 31-38.
  • Kim JM, Jeong JG, Ho SH, HahnW, Park EJ, Kim S, Yu SS, Lee YW, Kim S (2003) Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene Ther 10: 1543-1550.
  • Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383-385.
  • Lehrman S (1999) Virus treatment questioned after gene therapy death. Nature 401: 517-518.
  • Ma CH, Zhang Y, Wang XY, Gao LF, Liu H, Guo C, Liu SX, Cao YL, Zhang LN, SunWS (2004) Human endostatin gene transfer, either naked or with liposome, has the same inhibitory effect on growth of mouse liver tumor cells in vivo. World J Gastroenterol 10: 2874-2877.
  • Rezacova M, Vavrova J, Vokurkova D, Tichy A, Knizek J, Psutka J (2005) The importance of abrogation of G2-phase arrest in combined effect of TRAIL and ionizing radiation. Acta Biochim Polon 52: 889-895.
  • Rochlitz CF (2000) Gene therapy of cancer. Drugs Today Barc 36: 619-629.
  • Shen YL, Xia XX, Zhang Y, Liu JW, Wei DZ, Yang SL (2003) Refolding and purification of Apo2l/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. Biotechnol Lett 25: 2097-2101.
  • Shi J, Zheng D, Man K, Fan ST, Xu R (2003) TRAIL: a potential agent for cancer therapy. Curr Mol Med 3: 727-736.
  • Spierings DC, de Vries EG, Vellenga E, van den Heuvel FA, Koornstra JJ, Wesseling J, Hollema H, de Jong S (2004) Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 52: 821-831.
  • Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis inducing ligand in vivo. Nat Med 5: 157-163.
  • Wang J, Chen J, Wu M (2004) Expression and characterization of human tumor necrosis factor-related apoptosis inducing ligand in methylotrophic yeast Pichia pastoris. Ital J Biochem 53: 67-72.
  • Widlak W, Benedyk K, Vydra N, Glowala M, Scieglinska D, Malusecka E, Nakai A, Krawczyk Z (2003) Expression of a constitutively active mutant of heat shock factor 1 under the control of testis-specific hst70 gene promoter in transgenic mice induces degeneration of seminiferous epithelium. Acta Biochim Polon 50: 535-541.
  • Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y, Axel R (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 11: 223-232.
  • Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682.
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv54p307kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.